Neurological Blood-based Biomarkers and Cognitive Disorders in Critically Ill Survivors.
NCT ID: NCT05953311
Last Updated: 2023-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2023-06-23
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survival and Predictive Factors of Clinical Outcome in Patients With Acquired Brain Injury
NCT05968911
Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.
NCT03514524
S100B in Intensive Care Patients With and Without Traumatic Brain Injury
NCT04501315
Predictors of Better Outcomes After Severe Acquired Brain Injuries
NCT04495192
New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study
NCT01773915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICU survivors
Cohort of patients who survive an ICU stay of at least 7 days
Blood analysis
Blood analysis for neurological biomarkers measurements
Cognitive tests
Questionnaires assessing cognitive function
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood analysis
Blood analysis for neurological biomarkers measurements
Cognitive tests
Questionnaires assessing cognitive function
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* French speaking
Exclusion Criteria
* mental retardation
* known cognitive disorders or dementia
* ICU admission for neurological disease
* refusal
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Liege
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Françoise Rousseau, MD, PhD
Role: STUDY_DIRECTOR
University hospital of Liège
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Liège
Liège, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COGNISI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.